ANB033 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Tata Power targets 2.8 GW data-centre opportunity pipeline as Rs 15,000cr Mumbai grid plan advances

Fluence wins Vattenfall’s 1 GWh German battery storage contract as shares face pressure

Essar Oil & Gas adds five CBM blocks with 6.6 Tcf of gas in place

Essar Oil & Gas secures five coal-bed methane blocks with 6.6 Tcf gas-in-place potential

Editorial infographic showing an oil refinery at sunset with market-style chart lines and key ExxonMobil Q3 2026 indicators, including a $4.5 billion refining-margin uplift, a $1.3 billion upstream hit from lower liquids prices, a $2.5 billion timing effect, and an October 30, 2026 results date.

ExxonMobil signals $4.5bn refining earnings boost as oil-price pressure hits upstream

Read More

Pharma Industry News

First Tracks Biotherapeutics delivers major ANB033 trial win as celiac drug competition intensifies

First Tracks Biotherapeutics stock jumps on positive ANB033 celiac disease trial data. Discover what the results mean for investors and its growth outlook.

bySoujanya Ravi

October 14, 2026

web analytics